What is Sera Prognostics?
Founded to address critical gaps in maternal and newborn health, Sera Prognostics specializes in creating diagnostic tests designed for the early prediction of a woman's individualized risk for premature birth, preeclampsia, and other pregnancy complications. By providing actionable insights, Sera Prognostics empowers healthcare providers and expectant mothers with the information needed to implement timely and personalized treatment and care plans, aiming to improve outcomes for both mother and child. The company's approach is rooted in data-driven diagnostics, offering a proactive strategy in a field often characterized by reactive interventions.
How much funding has Sera Prognostics raised?
Sera Prognostics has raised a total of $325M across 11 funding rounds:
Debt
$4.5M
Private Equity
$9.2M
Private Equity
$5M
Series B
$25M
Debt
$10M
Series C
$40M
Series D
$36M
Debt
$1M
Series E
$100M
Share Placement
$75M
Debt (2013): $4.5M led by Catalyst Health Ventures, InterWest Partners, Linden, and UpStart Ventures
Private Equity (2014): $9.2M, investors not publicly disclosed
Private Equity (2014): $5M, investors not publicly disclosed
Series B (2015): $25M backed by Catalyst Health Ventures, Bill & Melinda Gates Foundation, InterWest Partners, and Domain Associates
Debt (2015): $10M with participation from Square 1 Bank
Series C (2017): $40M led by Laboratory Corporation of America, Bill & Melinda Gates Foundation, InterWest Partners, Catalyst Health Ventures, and Domain Associates
Series D (2019): $36M supported by Catalyst Health Ventures, InterWest Partners, Labcorp, Domain Associates, Chione , Ltd, and Blue Ox Healthcare Partners
Debt (2020): $1M featuring PPP
Series E (2021): $100M backed by Blue Ox Healthcare Partners, Anthem, aMoon, Parian Global, and Vivo Capital
Share Placement (2021): $75M, investors not publicly disclosed
Key Investors in Sera Prognostics
Catalyst Health Ventures
Catalyst Health Ventures is a VC firm specializing in early-stage biotech and healthcare innovations, dedicated to enhancing the health innovation ecosystem through strategic partnerships and programs that address complex healthcare challenges.
Bill & Melinda Gates Foundation
The Bill & Melinda Gates Foundation is a global organization focused on improving health and reducing poverty, supporting initiatives that advance health equity and access to essential services worldwide.
Domain Associates
Domain Associates is a venture capital firm established in 1985, with a strong specialization in biotech investments, managing multiple funds and a history of supporting numerous biopharmaceutical, device, and diagnostic companies.
What's next for Sera Prognostics?
With substantial enterprise-level funding and strategic investments, Sera Prognostics is positioned for accelerated growth and market penetration. The company's ongoing development of predictive diagnostic tools for high-risk pregnancies indicates a strategic focus on expanding its portfolio and enhancing its technological capabilities. Future endeavors will likely involve scaling its commercial operations, further validating its tests through clinical studies, and potentially exploring new applications for its predictive analytics in women's health. The sustained capital infusion suggests a trajectory towards becoming a leader in precision diagnostics for pregnancy.
See full Sera Prognostics company page
